左氧氟沙星与头孢呋辛治疗肺炎的药物经济学分析(3)
[4]李岩.左氧氟沙星联合头孢曲松钠治疗肺炎的临床效果及安全性分析[J].中国医药指南,2019,17(21):23-24.
[5]胥绍军,介煜.左氧氟沙星与头孢呋辛对急性下呼吸道细菌感染患者的临床疗效与安全性比较[J].抗感染药学,2018,34(4):88-92.
[6]杨卫群.头孢克肟联合左氧氟沙星治疗慢性肺炎的有效性及安全性分析[J].健康之路,2018,34(3):107.
[7]柯礼业.千金苇茎汤加减联合左氧氟沙星治疗肺炎疗效分析[J].中医临床研究,2019,36(20):19-20.
[8] Shi W X,Wu S S,Gong C,et al.The epidemiological characteristics and drug resistance of mycoplasma pneumoniae in patients with community-acquired pneumonia during 2011-2015 in 5 sentinel hospitals in Beijing[J].Zhonghua Yu Fang Yi Xue Za Zhi, 2017,54(12):832-836.
[9]陳演增,王晓春,雷招宝,等.左氧氟沙星和头孢呋辛钠致麻疹样红斑与跟腱炎[J].药物不良反应杂志,2018,20(1):56-57.
[10] Geller M,Nunesa C P,Oliveira L,et al.Smaltophilia pneumonia:A case report[J].Respiratory Medicine Case Reports,2018,24(145):20-34.
[11]贺永强.探讨头孢哌酮舒巴坦联合左氧氟沙星治疗老年肺炎的疗效[J].特别健康,2017,154(14):45-46.
[12] Li-Feng W.Comparison of effect of levofloxacin with cefuroxime plus azithromycin on community-acquired Pneumonia[J].China Tropical Medicine,2012,13(342):123-135.
(收稿日期:2020-03-03) (本文编辑:张亮亮), 百拇医药(陈桂香 朱碧媛 赵思婷)
[5]胥绍军,介煜.左氧氟沙星与头孢呋辛对急性下呼吸道细菌感染患者的临床疗效与安全性比较[J].抗感染药学,2018,34(4):88-92.
[6]杨卫群.头孢克肟联合左氧氟沙星治疗慢性肺炎的有效性及安全性分析[J].健康之路,2018,34(3):107.
[7]柯礼业.千金苇茎汤加减联合左氧氟沙星治疗肺炎疗效分析[J].中医临床研究,2019,36(20):19-20.
[8] Shi W X,Wu S S,Gong C,et al.The epidemiological characteristics and drug resistance of mycoplasma pneumoniae in patients with community-acquired pneumonia during 2011-2015 in 5 sentinel hospitals in Beijing[J].Zhonghua Yu Fang Yi Xue Za Zhi, 2017,54(12):832-836.
[9]陳演增,王晓春,雷招宝,等.左氧氟沙星和头孢呋辛钠致麻疹样红斑与跟腱炎[J].药物不良反应杂志,2018,20(1):56-57.
[10] Geller M,Nunesa C P,Oliveira L,et al.Smaltophilia pneumonia:A case report[J].Respiratory Medicine Case Reports,2018,24(145):20-34.
[11]贺永强.探讨头孢哌酮舒巴坦联合左氧氟沙星治疗老年肺炎的疗效[J].特别健康,2017,154(14):45-46.
[12] Li-Feng W.Comparison of effect of levofloxacin with cefuroxime plus azithromycin on community-acquired Pneumonia[J].China Tropical Medicine,2012,13(342):123-135.
(收稿日期:2020-03-03) (本文编辑:张亮亮), 百拇医药(陈桂香 朱碧媛 赵思婷)